Search Results - "Hackmann, John"

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial by Untch, Michael, Prof, Jackisch, Christian, Prof, Schneeweiss, Andreas, Prof, Conrad, Bettina, MD, Aktas, Bahriye, MD, Denkert, Carsten, Prof, Eidtmann, Holger, MD, Wiebringhaus, Hermann, MD, Kümmel, Sherko, MD, Hilfrich, Jörn, Prof, Warm, Mathias, Prof, Paepke, Stefan, MD, Just, Marianne, MD, Hanusch, Claus, MD, Hackmann, John, MD, Blohmer, Jens-Uwe, Prof, Clemens, Michael, Prof, Darb-Esfahani, Silvia, MD, Schmitt, Wolfgang Daniel, MD, Dan Costa, Serban, Prof, Gerber, Bernd, Prof, Engels, Knut, MD, Nekljudova, Valentina, PhD, Loibl, Sibylle, Prof, von Minckwitz, Gunter, Prof

“…Summary Background In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based…”
Get full text

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial by Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, Harbeck, Nadia

“…Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates of pathological complete response (pCR)…”
Get full text

RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial by Heil, Joerg, Sinn, Peter, Richter, Hannah, Pfob, André, Schaefgen, Benedikt, Hennigs, André, Riedel, Fabian, Thomas, Bettina, Thill, Marc, Hahn, Markus, Blohmer, Jens-Uwe, Kuemmel, Sherko, Karsten, Maria Margarete, Reinisch, Mattea, Hackmann, John, Reimer, Toralf, Rauch, Geraldine, Golatta, Michael

“…Neoadjuvant chemotherapy (NACT) is a standard approach of the multidisciplinary treatment of breast cancer. Depending on the biological subtype a pathological…”
Get full text

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial by Graeser, Monika, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich, Harbeck, Nadia

“…BackgroundThe association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in…”
Get full text

A systematic and sensitive method for critical reagent antibody evaluation with PCA technology by Gong, Jian, Wang, Xing, Hackmann, John

“…Quality control of critical reagents is essential in basic research and in drug discovery and development. Protein conformational array (PCA) is an ELISA-based…”
Get full text

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto by Untch, Michael, Jackisch, Christian, Schneeweiss, Andreas, Schmatloch, Sabine, Aktas, Bahriye, Denkert, Carsten, Schem, Christian, Wiebringhaus, Hermann, Kümmel, Sherko, Warm, Mathias, Fasching, Peter A, Just, Marianne, Hanusch, Claus, Hackmann, John, Blohmer, Jens-Uwe, Rhiem, Kerstin, Schmitt, Wolfgang D, Furlanetto, Jenny, Gerber, Bernd, Huober, Jens, Nekljudova, Valentina, von Minckwitz, Gunter, Loibl, Sibylle

“…The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate…”
Get full text

Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery by Pfob, André, Sidey-Gibbons, Chris, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria, Golatta, Michael, Heil, Joerg

“…Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in 40%-70% of women with breast cancer. These patients may not need surgery as all…”
Get full text

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03 by Heil, Joerg, Pfob, André, Sinn, Hans-Peter, Rauch, Geraldine, Bach, Paul, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Ditsch, Nina, Rody, Achim, Große, Regina, van Mackelenbergh, Marion, Reinisch, Mattea, Karsten, Maria, Golatta, Michael

“…OBJECTIVE:We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the…”
Get full text

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials by Villegas, Sonia L., Nekljudova, Valentina, Pfarr, Nicole, Engel, Jutta, Untch, Michael, Schrodi, Simone, Holms, Frank, Ulmer, Hans U., Fasching, Peter A., Weber, Karsten E., Albig, Christian, Heinrichs, Clemens, Marmé, Frederik, Hartmann, Arndt, Hanusch, Claus, Schmitt, Wolfgang D., Huober, Jens, Lederer, Bianca, van Mackelenbergh, Marion, Tesch, Hans, Jackisch, Christian, Rezai, Mahdi, Sinn, Peter, Sinn, Bruno V., Hackmann, John, Kiechle, Marion, Schneeweiss, Andreas, Weichert, Wilko, Denkert, Carsten, Loibl, Sibylle

“…To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in…”
Get full text

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial by Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Paré, Laia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jóźwiak, Katarzyna, Zu Eulenburg, Christine, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemotherapy appears to be an option in selected…”
Get full text

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial by Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia, von Schumann, Raquel, Kuhn, Walther, Polata, Silke, Bielecki, Wojciech, Meyer, Ralf, Just, Marianne, Kraudelt, Susanne, Siggelkow, Wulf, Wortelmann, Heidi, Kleine-Tebbe, Anke, Leitzen, Lena, Kirchhof, Heidrun, Krabisch, Petra, Hackmann, John, Depenbusch, Reinhard, Gnauert, Karsten, Staib, Peter, Lehnert, Antje, Hoffmann, Oliver, Briest, Susanne, Lindner, Christoph, Heyl, Volker, Bauer, Leila, Uleer, Christoph, Mohrmann, Svjetlana, Viehstaedt, Nicole, Malter, Wolfram, Link, Theresa, Buendgen, Nana, Tio, Joke

“…Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological…”
Get full text

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial by Gluz, Oleg, Kolberg‐Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Paré, Laia, Grischke, Eva‐Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich, Harbeck, Nadia

“…In the neoadjuvant WSG‐ADAPT‐TN trial, 12‐week nab‐paclitaxel + carboplatin (nab‐pac/carbo) was highly effective and superior to nab‐paclitaxel + gemcitabine…”
Get full text

Abstract P2-16-05: Efficacy of response- and toxicity-guided neoadjuvant chemotherapy in elderly early breast cancer patients: Results of WSG ADAPT elderly sub-trial by Kuemmel, Sherko, Gluz, Oleg, Christgen, Matthias, Potenberg, Jochem, Hackmann, John, von Schumann, Raquel, Graeser, Monika, Mangold, Marina, Wuerstlein, Rachel, Kates, Ronald, Kreipe, Hans H., Nitz, Ulrike, Harbeck, Nadia

“…Abstract Introduction: More than 1/3 of early breast cancers (EBC) are diagnosed in women ≥ 70 years. Although polychemotherapy has been shown to be more…”
Get full text

Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept by Pfob, André, Cai, Lie, Schneeweiss, Andreas, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria Margarete, Sidey-Gibbons, Chris, Wallwiener, Markus, Golatta, Michael, Heil, Joerg

“…Background Breast cancer patients with residual disease after neoadjuvant systemic treatment (NAST) have a worse prognosis compared with those achieving a…”
Get full text

ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept by Pfob, André, Cai, Lie, Schneeweiss, Andreas, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria Margarete, Sidey-Gibbons, Chris, Wallwiener, Markus, Golatta, Michael, Heil, Joerg

Get full text

Abstract PD7-02: Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery by Pfob, André, Sidey-Gibbons, Chris, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, Große, Regina, van Mackelenbergh, Marion, Reinisch, Mattea, Karsten, Maria, Golatta, Michael, Heil, Joerg

“…Abstract Background: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response (pCR, ypT0, ypN0) in 40-70% of women with HER2 positive,…”
Get full text

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52) by von Minckwitz, Gunter, Conrad, Bettina, Reimer, Toralf, Decker, Thomas, Eidtmann, Holger, Eiermann, Wolfgang, Hackmann, John, Möbus, Volker, Marmé, Frederik, Potenberg, Jochem, Stickeler, Elmar, Simon, Eike, Thomssen, Christoph, Huober, Jens, Denkert, Carsten, Alfer, Joachim, Jackisch, Christian, Nekljudova, Valentina, Burchardi, Nicole, Loibl, Sibylle

“…BACKGROUND Although greater than 40% of breast cancers occur in patients aged ≥65 years, these individuals are frequently undertreated. Taxane‐based adjuvant…”
Get full text

Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial by Biehl, Claudia, Kolberg-Liedtke, Cornelia, Gluz, Oleg, Feuerhake, Friedrich, Christgen, Matthias, Kates, Ronald, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, de Haas, Sanne L, Deurloo, Regula, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans H., Harbeck, Nadia

“…Abstract Background: Among patients with highly heterogeneous HER2+ breast cancer (BC), pathological complete response (pCR) (ypT0/is/ypN0) is associated with…”
Get full text

The BrEasT cancer afTER-CARE (BETTER-CARE) programme to improve breast cancer follow-up: design and feasibility study results of a cluster-randomised complex intervention trial by Horn, Anna, Wendel, Julia, Franke, Isabella, Bauer, Armin, Baumeister, Harald, Bendig, Eileen, Brucker, Sara Y., Deutsch, Thomas M., Garatva, Patricia, Haas, Kirsten, Heil, Lorenz, Hügen, Klemens, Manger, Helena, Pryss, Rüdiger, Rücker, Viktoria, Salmen, Jessica, Szczesny, Andrea, Vogel, Carsten, Wallwiener, Markus, Wöckel, Achim, Heuschmann, Peter U., Ast, Alexander, Belke, Kerstin, Beurer, Björn, Bolkenius, Petra, Freese, Kristina, Frumkin, Nora, Gnauert, Karsten, Graf, Heiko, Hackmann, John, Hartmann, Corinna, Hesse, Tobias, Hopp, Melanie, Keil, Elke, Lehnert, Antje, Müller, Cordula, Mundhenke, Christoph, Niestroj, Hue Phan, Nixdorf, Antje, Pankert, Kilian, Perez, Sibylle, Radosa, Julia, Rezek, Daniela, Seldte, Jens-Paul, Stalzer, Gabriele, Sykorova, Zuzana, Tenger, Martin, Volmer, Léa, Würfel, Katharina, Zorr, Andreas

“…Abstract Background The risk of breast cancer patients for long-term side effects of therapy such as neurotoxicity and cardiotoxicity as well as late effects…”
Get full text

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results by Gluz, Oleg, Nitz, Ulrike, Liedtke, Cornelia, Christgen, Matthias, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Bangemann, Nikola, Lindner, Christoph, Kuemmel, Sherko, Clemens, Michael, Potenberg, Jochem, Staib, Peter, Kohls, Andreas, von Schumann, Raquel, Kates, Ronald, Kates, Ronald, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Abstract Background Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal…”
Get full text